A Phase II Study of ABC294640 in Patients With Advanced Hepatocellular Carcinoma Who Have Progressed on Sorafenib
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs ABC 294640 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors RedHill Biopharma
- 21 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Feb 2017 Status changed from not yet recruiting to recruiting.
- 18 Oct 2016 Status changed from planning to not yet recruiting.